Meeting
2019 ASCO Annual Meeting
A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Authors
Brian Andrew Van Tine
Washington University in St. Louis, St. Louis, MO
Brian Andrew Van Tine , Nam Bui , Bethany Prudner , John S. Bomalaski , Bor-Wen Wu , Sant P. Chawla , Kristen N. Ganjoo , Peter John Oppelt , Angela C. Hirbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03449901
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS11079)
DOI
10.1200/JCO.2019.37.15_suppl.TPS11079
Abstract #
TPS11079
Poster Bd #
399b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
First Author: Ghazal Tansir
Poster
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
First Author: Andrew Eugene Hendifar
Poster
2015 ASCO Annual Meeting
A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo